Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs.

BACKGROUND Vomiting, nausea, inappetence, and diarrhea are common delayed adverse effects of doxorubicin. Maropitant, a neurokinin-1 receptor antagonist, is known to prevent acute vomiting in dogs receiving cisplatin. OBJECTIVE To evaluate the efficacy of maropitant in preventing delayed vomiting after administration of doxorubicin to dogs. ANIMALS Fifty-nine dogs with cancer. METHODS This randomized, double-blind, placebo-controlled study used a cross-over design. Dogs were randomized into 1 of 2 treatment groups. Group A received maropitant after the 1st doxorubicin, and placebo after the 2nd. Group B received placebo first, and maropitant second. Maropitant (2 mg/kg) or placebo tablets were administered PO for 5 days after doxorubicin treatment. Owners completed visual analog scales based on Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events to grade their pet's clinical signs during the week after administration of doxorubicin. Statistical differences in gastrointestinal toxicosis and myelosuppression between maropitant and placebo treatments were evaluated. RESULTS Significantly fewer dogs had vomiting (P=.001) or diarrhea (P=.041), and the severity of vomiting (P<.001) and diarrhea (P=.024) was less the week after doxorubicin when receiving maropitant compared with placebo. No differences were found between maropitant and placebo for other gastrointestinal and bone marrow toxicoses. CONCLUSIONS AND CLINICAL IMPORTANCE Maropitant is effective in preventing delayed vomiting induced by doxorubicin. Its prophylactic use might improve quality of life and decrease the need for dose reductions in certain dogs.

[1]  R. Navari.  Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting , 2012, Drugs.

[2]  D. Tweardy,et al.  Substance P Receptor Antagonism for Treatment of Cryptosporidiosis in Immunosuppressed Mice , 2008, The Journal of parasitology.

[3]  R. Di Fabio,et al.  Neurokinin 1 receptor antagonists--current prospects. , 2007, Current opinion in drug discovery & development.

[4]  J. Boucher,et al.  The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. , 2007, Journal of veterinary pharmacology and therapeutics.

[5]  D. Vail,et al.  Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients. , 2007, Veterinary and comparative oncology.

[6]  T. Rowan,et al.  Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. , 2007, American journal of veterinary research.

[7]  C. Pothoulakis,et al.  Immunomodulatory Properties of Substance P , 2006, Annals of the New York Academy of Sciences.

[8]  M. Kris,et al.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Vail.  Veterinary Co-operative Oncology Group. , 2004, Veterinary and comparative oncology.

[10]  F. Shanahan,et al.  The role of substance P in inflammatory disease , 2004, Journal of cellular physiology.

[11]  R. Navari.  Role of Neurokinin-1 Receptor Antagonists in Chemotherapy-Induced Emesis: Summary of Clinical Trials , 2004, Cancer investigation.

[12]  J. Weinstock,et al.  Substance P expression correlates with severity of diarrhea in cryptosporidiosis. , 2003, The Journal of infectious diseases.

[13]  F. Schnell.  Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. , 2003, The oncologist.

[14]  M. Palmer,et al.  Treatment with Neurokinin-1 Receptor Antagonist Reduces Severity of Inflammatory Bowel Disease Induced by Cryptosporidium parvum , 2002, Clinical and Vaccine Immunology.

[15]  Diarmuid P. O'Donoghue,et al.  Human colonic anti‐secretory activity of the potent NK1 antagonist, SR140333: assessment of potential anti‐diarrhoeal activity in food allergy and inflammatory bowel disease , 2001, British journal of pharmacology.

[16]  F. Tonelli,et al.  Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine. , 2000, The American journal of pathology.

[17]  E. Perez,et al.  ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[18]  C. Pothoulakis,et al.  Substance P receptor expression in intestinal epithelium in clostridium difficile toxin A enteritis in rats. , 1998, The American journal of physiology.

[19]  U. Holzer‐Petsche,et al.  Tachykinins in the gut. Part I. Expression, release and motor function. , 1997, Pharmacology & therapeutics.

[20]  U. Holzer‐Petsche,et al.  Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. , 1997, Pharmacology & therapeutics.

[21]  G. Ogilvie,et al.  Surgery and doxorubicin in dogs with hemangiosarcoma. , 1996, Journal of veterinary internal medicine.

[22]  P. Hellström,et al.  Tachykinins increase vascular permeability in the gastrointestinal tract of the rat. , 1996, Acta physiologica Scandinavica.

[23]  W. Rand,et al.  Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. , 1995, Journal of the American Veterinary Medical Association.

[24]  K. Das,et al.  Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. , 1992, The American journal of gastroenterology.

[25]  G. Ogilvie,et al.  Phase II evaluation of doxorubicin for treatment of various canine neoplasms. , 1989, Journal of the American Veterinary Medical Association.

[26]  G. Ogilvie,et al.  Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. , 1989, Journal of the American Veterinary Medical Association.